HomeCompareANGN vs MRK

ANGN vs MRK: Dividend Comparison 2026

ANGN yields 200.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANGN wins by $119.31M in total portfolio value
10 years
ANGN
ANGN
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full ANGN calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ANGN vs MRK

📍 ANGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANGNMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANGN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANGN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANGN
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ANGN beats the other by $51,141,353.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANGN + MRK for your $10,000?

ANGN: 50%MRK: 50%
100% MRK50/50100% ANGN
Portfolio after 10yr
$59.71M
Annual income
$30,092,947.21/yr
Blended yield
50.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ANGN
Analyst Ratings
1
Buy
3
Hold
Consensus: Hold
Price Target
$1.50
+50.0% upside vs current
Range: $1.50 — $1.50
Altman Z
-16.3
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANGN buys
0
MRK buys
0
No recent congressional trades found for ANGN or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANGNMRK
Forward yield200.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$119.36M$56.8K
Annual income after 10y$60,176,096.29$9,798.13
Total dividends collected$112.49M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$1.50$128.54

Year-by-year: ANGN vs MRK ($10,000, DRIP)

YearANGN PortfolioANGN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$30,700$20,000.00$11,206$366.19+$19.5KANGN
2$90,232$57,383.18$12,650$502.35+$77.6KANGN
3$254,173$157,624.56$14,407$694.19+$239.8KANGN
4$686,927$414,961.74$16,585$967.82+$670.3KANGN
5$1,783,118$1,048,106.39$19,342$1,363.89+$1.76MANGN
6$4,450,613$2,542,677.12$22,913$1,947.19+$4.43MANGN
7$10,693,420$5,931,263.38$27,662$2,823.89+$10.67MANGN
8$24,760,608$13,318,648.86$34,159$4,173.35+$24.73MANGN
9$55,315,649$28,821,798.66$43,337$6,308.80+$55.27MANGN
10$119,363,841$60,176,096.29$56,776$9,798.13+$119.31MANGN

ANGN vs MRK: Complete Analysis 2026

ANGNStock

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Full ANGN Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ANGN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANGN vs SCHDANGN vs JEPIANGN vs OANGN vs KOANGN vs MAINANGN vs JNJANGN vs ABBVANGN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.